The effect of vitamin A supplementation in outpatients with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20210102049912N1
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Having clinical signs and test results that confirm COVID-19
CRP level higher than 0.3 mg per liter
Having an ESR higher than 22 mm per hour for women and 29 mm per hour for men

Exclusion Criteria

Having any autoimmune disease (lupus, MS, etc.)
Suffering from diseases that interfere with the absorption of vitamin A.
Consumers of vitamin A supplements
Patients with severe renal insufficiency and dialysis
Patients with underlying liver disease
Pregnancy
Lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical symptoms improvement. Timepoint: Before the intervention and 10 days after the start of the intervention. Method of measurement: Definition of clinical improvement includes normalization of body temperature (=37.2's,) number of breaths (= 24 breaths per minute,) oxygen saturation (> 94% at room temperature) that is stable for at least 24 hours.;Hospitalization. Timepoint: Ten days after the start of the intervention. Method of measurement: Patients' hospitalization will be recorded using a questionnaire and their follow-up.;C-reactive protein. Timepoint: Before the intervention and 10 days after the intervention. Method of measurement: Hemagglutination.;Erythrocyte Sedimentation Rate. Timepoint: Before the intervention and 10 days after the intervention. Method of measurement: Erythrocyte Sedimentation test.